

Temporal Variability of Oral Microbiota over 10 Months and the Implications for Future Epidemiologic Studies

Emily Vogtmann¹, Xing Hua², Liang Zhou¹, Yunhu Wan², Shalabh Suman^{3,4}, Bin Zhu^{3,4}, Casey L. Dagnall^{3,4}, Amy Hutchinson^{3,4}, Kristine Jones^{3,4}, Belynda D. Hicks^{3,4}, Rashmi Sinha¹, Jianxin Shi², and Christian C. Abnet¹



Abstract

Background: Few studies have prospectively evaluated the association between oral microbiota and health outcomes. Precise estimates of the intrasubject microbial metric stability will allow better study planning. Therefore, we conducted a study to evaluate the temporal variability of oral microbiota.

Methods: Forty individuals provided six oral samples using the OMNIgene ORAL kit and Scope mouthwash oral rinses approximately every two months over 10 months. DNA was extracted using the QIAasympphony and the V4 region of the 16S rRNA gene was amplified and sequenced using the MiSeq. To estimate temporal variation, we calculated intraclass correlation coefficients (ICCs) for a variety of metrics and examined stability after clustering samples into distinct community types using Dirichlet multinomial models (DMMs).

Results: The ICCs for the alpha diversity measures were high, including for number of observed bacterial species [0.74; 95% confidence interval (CI): 0.65–0.82 and 0.79; 95% CI: 0.75–0.94] from OMNIgene ORAL and Scope mouthwash, respectively. The ICCs for the relative abundance of the top four phyla and beta diversity matrices were lower. Three clusters provided the best model fit for the DMM from the OMNIgene ORAL samples, and the probability of remaining in a specific cluster was high (59.5%–80.7%).

Conclusions: The oral microbiota appears to be stable over time for multiple metrics, but some measures, particularly relative abundance, were less stable.

Impact: We used this information to calculate stability-adjusted power calculations that will inform future field study protocols and experimental analytic designs. *Cancer Epidemiol Biomarkers Prev*; 27(5); 594–600. ©2018 AACR.

Introduction

Tooth loss and periodontal disease have been found to be associated with mortality (1, 2) and cancer (3, 4), which bolster the hypothesis that oral microbiota is associated with human health. Oral microbial differences have been observed in individuals with adverse health conditions such as pancreatic cancer (5–7), but the majority of studies have been conducted cross-sectionally, which precludes understanding the temporality of the effects, including an oral sample from a single timepoint.

Use of an oral sample from a single timepoint for epidemiologic studies of the microbiome will be effective if the microbial characteristics are fairly stable over time. However, if the oral microbiota is highly variable, collection of multiple oral samples would improve the power to detect associations with specific outcomes. Some previous studies considering the temporal variation in the oral microbiome within healthy individuals have concluded that oral microbiota is fairly stable over time (8–20) while others have suggested instability in oral microbiota (20–23). However, there have been limitations to many of the published studies including nonstandard assessments of stability, limited sample sizes, few samples collected per individual, and testing of only short time intervals.

Given these limitations, we conducted a study of 40 individuals who provided oral samples for a total of six visits, approximately every two months, using two collection methods. We used these samples to determine the temporal variability in oral microbiota using a variety of conceptual models. The results of this study have important implications for future oral microbiota studies and can be used to help determine the most appropriate sample size and number of sample timepoints for collection from each individual.

Materials and Methods

Study population

We recruited a convenience sample cohort of 40 adults working at the National Cancer Institute in the fall of 2014

¹Metabolic Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland. ²Biostatistics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland. ³Cancer Genomics Research Laboratory, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland. ⁴Leidos Biomedical Research Laboratory, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Data availability: The raw sequencing data are available through the NCBI Sequence Read Archive (SRP130106).

Corresponding Author: Emily Vogtmann, National Cancer Institute, 9609 Medical Center Dr, MSC 9768, Bethesda, MD 20892. Phone: 240-276-6701; Fax: 240-276-7837; E-mail: emily.vogtmann@nih.gov

doi: 10.1158/1055-9965.EPI-17-1004

©2018 American Association for Cancer Research.

by e-mail and word of mouth. Potential participants who were not planning on working at the National Cancer Institute for at least one year were advised not to participate. Participants received no monetary compensation and provided written informed consent. This study was approved by the Special Studies Institutional Review Board of the National Cancer Institute.

Oral sample collection

Oral samples were collected from participants approximately every two months for a total of six visits. In the 12 hours prior to the scheduled visit, participants were asked to refrain from dental hygiene procedures (including tooth brushing, flossing, and use of mouthwash or other dental rinse products), eating, drinking (other than water), chewing gum, consuming throat lozenges or candies, smoking cigarettes, or chewing tobacco.

At the baseline visit, participants provided two consecutive oral samples, both using the OMNIgene ORAL collection kit (DNA Genotek; Ottawa, Ontario, Canada). At all other visits, the participants provided a single oral sample using the OMNIgene ORAL kit. Participants spit into the kit until the saliva reached the fill line, the kit was closed to release the fixative, a cap was placed on the tube to replace the funnel, and then the tube was shaken. These samples were stored for up to 16 days at room temperature and transferred to the laboratory where they were shaken and then incubated at 50°C for 1 hour in a water bath, aliquoted, and frozen at -80°C. At the second and sixth visit, the participants provided an additional oral sample using Scope mouthwash after completing the OMNIgene ORAL collection. Using the protocol for the NHANES oral wash collection (24), the participant was instructed to swish 10 mL of Scope mouthwash from a sterile cup for 5 seconds and then gargle for 5 seconds and repeat for a total of 30 seconds. After the 30 seconds, the mouthwash was spit back into the sterile cup. The Scope mouthwash samples were stored for up to 2 days at room temperature and then transferred to the laboratory, aliquoted, and frozen at -80°C.

Questionnaire

At each sample collection, participants filled out a short electronic questionnaire which included questions regarding adherence to the preparation procedures, oral health practices, and tobacco, alcohol, and antibiotic use. We also obtained demographic information and self-reported height and weight.

DNA extraction, amplification, and sequencing

For DNA extraction, samples were grouped by collection method (OMNIgene ORAL or Scope mouthwash) and then batched into 23 samples for extraction, keeping all samples from each individual, of the same source material, within one extraction batch to limit technical variation due to batch effects. Each batch also included three quality control samples: (i) either an oral artificial community or a chemostat community (25); (ii) a blank; and (iii) an extraction duplicate of a randomly selected sample. For the OMNIgene ORAL samples, the vials were thawed at 4°C and then incubated for one hour at 50°C with vortexing every 20 minutes. An aliquot of 1,000 µL was then incubated for an additional 15 minutes at 75°C before DNA extraction. For the Scope mouthwash samples, the vials were thawed at 4°C and then 1,000 µL was transferred into a Pathogen Lysis Tube-L (Qiagen) and pelleted. After removing

the supernatant, 894 µL of Buffer ATL (Qiagen) and 6 µL of Reagent DX solution (Qiagen) were added to each tube. Cells were lysed by vortexing the bead and buffer mixture for 20 minutes. For the artificial community and chemostat samples, similar procedures to the Scope mouthwash were used, except there was no pelleting step. After pretreatment, DNA was extracted from all samples using the DSP DNA Virus Pathogen kit (Qiagen) on a QIASymphony instrument (Qiagen) following a modified Complex800_V6_DSP protocol.

For each sample, 20 ng of DNA, as measured by Quant-iT PicoGreen dsDNA (Thermo Fisher Scientific) quantitation, was split into 10 ng (1 ng/µL) aliquots for two separate PCR reactions. PCR was performed in 25 µL reaction volumes consisting of: 10 ng (10 µL) of DNA, 10 µL of 2.5× HotMasterMix (5 PRIME), 3 µL of MBG water, and 2 µL of the 5 µmol/L 16S rRNA V4 (515F/806R) barcoded primer mix that was composed of equimolar forward and reverse primer pairs. The primers were ordered from Integrated DNA Technologies. A total of 192 unique barcodes were used, resulting in 192 unique forward/reverse primer pair mixes that could be used for amplification. The 515F forward PCR primer sequence was AATGATACGGCGACCACCGAGATCTACAC TATGTAATT GT GTGCCAGCMGCCGCGGTAA, consisting of the 5' Illumina adapter, forward primer pad, forward primer linker, and forward primer. The 806R reverse PCR primer sequence was CAAGCAGAAGACGGCATAACGAGAT XXXXXXXX-XXXX AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT, consisting of the reverse complement of the 3' Illumina adapter, Golay barcode (defined by X, 12 bp barcode identifier generated specifically for this primer set), reverse primer pad, reverse primer linker, and reverse primer (26). Thermal cycling was performed on a GeneAmp PCR 9700 system (Thermo Fisher Scientific) where PCR conditions consisted of: 94°C hold for 3 minutes, denature at 94°C for 45 seconds, anneal at 50°C for 1 minute, extend at 72°C for 1 minute 30 seconds for 25 cycles, followed by a 72°C hold for 10 minutes.

Sample PCR replicates were then pooled and purified using a 1:1 AMPure XP (Beckman Coulter Genomics) ratio, performing the final elution in 30 µL of Buffer EB (Qiagen). Amplified sample libraries were quantified using Quant-iT PicoGreen dsDNA Reagent and up to 96, with unique barcoded adapters, were combined in equal amounts (100 ng each) and pools normalized to 10 nmol/L with Buffer EB for pooled sequencing.

For DNA sequencing, the Illumina MiSeq v2, 500 cycle kit was used (Illumina) following the manufacturer's protocol with modifications (27). Pooled libraries were diluted to 5 pmol/L in a serial dilution, and 25% denatured 5 pmol/L PhiX was spiked-in and added to the "Load Sample" well. A total of 3.4 µL of Index Sequencing Primer at 100 mmol/L, 3.4 µL of Read 1 Sequencing primer at 100 mmol/L, and 3.4 µL of Read 2 Sequencing Primer at 100 µmol/L was added to wells 13, 12, and 14 of the MiSeq sequencing cartridge. 2 × 250 bp paired end sequencing was performed on the MiSeq, with up to 96 samples per run.

Bioinformatic data processing

From the Illumina MiSeq, the sequence files were demultiplexed using the bcl-to-fastq converter from CASAVA. The DADA2 pipeline 1.2.1 was used to generate sequence variant tables and phylogenetic trees based on paired-end sequence reads (28). For quality filtering, the sequences were trimmed at 10 and 220 base pairs for forward reads and 220 base pairs for reverse reads. The reads were then merged using the

default mergePairs function in DADA2. After merging and error correction, sequence variants (i.e., 100% OTUs) were identified. After removal of chimeras, using removeBimeraDenovo, a total of 90% of the sequence reads were retained. The detected sequence variants were then aligned with the SILVA v123 database for taxonomy assignment (29). Sequences which aligned to mitochondria were removed. From 505 samples, 1,531 sequence variants were identified in total that included 16 phyla, 25 classes, 50 orders, 86 families, and 225 genera. An average of 84,787 sequences were generated per sample.

Using QIIME 1.9.1, relative abundances, alpha and beta diversity metrics were calculated (30). The relative abundance tables ranging from the phylum to genus level were generated for each sample without rarefaction. Alpha diversity metrics including Chao1 (31), observed species, Shannon index (32), and PD whole tree (33) were calculated on the basis of the average of 10 subsamples with rarefaction at 30,000 reads. These alpha diversity metrics measure richness and/or evenness of the bacteria in the samples. The beta diversity matrices, Bray-Curtis (34), unweighted UniFrac, and weighted UniFrac (35), in addition to the principal coordinates from those matrices were generated on the basis of rarefaction at 30,000 reads. Beta diversity measures the microbial composition of the samples and utilizes relative abundance data in the Bray-Curtis and weighted UniFrac matrices and presence/absence data for unweighted UniFrac, while phylogenetic tree data is included for both UniFrac matrices. Of the blank samples with any amplification, the median number of reads was 18 and all blank samples were removed after rarefaction at 30,000 reads. A principal coordinates analysis (PCoA) plot using the first two principal coordinates from each beta diversity matrix was generated to visually inspect clustering of the oral artificial community, the chemostat community, and the individual participant samples. The intraclass correlation coefficients (ICC) for the extraction duplicates were all greater than or equal to 0.94 for the alpha diversity metrics, 0.93 for the first two principal coordinates of the beta diversity matrices, and 0.96 for the relative abundances of the top four phyla. For the artificial community and chemostat samples, the coefficient of variation was less than or equal to 8% and 6%, respectively, for all alpha diversity metrics.

Statistical analysis

To quantify temporal variability, we calculated ICCs for the alpha diversity metrics and the square root of the relative abundance of the most abundant taxa at the phylum and genus level. For each microbiome metric, we estimated the between subject variance σ_b^2 and the within subject variance σ_w^2 using a linear mixed effect model from the lme4 package and estimated the ICC as $\sigma_b^2/(\sigma_b^2 + \sigma_w^2)$. The ICCs were calculated for the OMNIgene ORAL samples from the 6 visits (7 samples for each subject including 2 at baseline) and Scope mouthwash from 2 visits (2 samples for each subject). We calculated 95% confidence intervals (CIs) for each ICC based on 100 random bootstrap samplings. To diminish a potential inflation of the ICC for the repeated measurement of the OMNIgene ORAL samples at the first visit, we included a fixed effect for visit in the mixed model. We estimated the impact of adjusting the model individually for use of antibiotics, having a dental visit in the past 2 months, and not adhering to the preparation procedures prior to the visit. For the beta diversity metrics, a distance-based

ICC was calculated on the basis of the three distance matrices. The 95% CIs for each distance-based ICC was also calculated on the basis of 100 random bootstrap samplings.

As another measure of temporal variability, we used a Dirichlet multinomial mixture model (DMM; ref. 36) to cluster the OMNIgene ORAL samples into community types by modeling the abundances of all taxa at each taxonomic level. The number of microbial community types was determined by minimizing the Bayesian Information Criterion (BIC). The OMNIgene ORAL samples were assigned to their community type based on the maximum posterior probability. We then characterized the temporal dynamics of microbiome community types using a Markov model (22). The transition probabilities of the Markov model were estimated from the maximum posterior probability using the microbial data from all subjects and a high probability of remaining in the same cluster would indicate temporal stability.

We also investigated the impact of the estimated ICC from the OMNIgene ORAL and Scope mouthwash samples for total sample sizes (N) required to detect differences between cases and an equal number of controls. We calculated the required sample size to detect a specific OR comparing the top quartile to the bottom quartile for a given microbial measurement from the estimated ICCs for the OMNIgene ORAL and Scope mouthwash samples assuming 80% power, a disease prevalence of 1%, and 1, 2, or 3 samples per individual. The required sample sizes were calculated for a range of P value thresholds to account for multiple testing.

All statistical analyses were conducted using R (version 3.3.2), except for the Dirichlet multinomial mixture model which was fitted by using MicrobeDMM (<https://code.google.com/archive/p/microbedmm/downloads>).

Results

As seen in Table 1, the majority of participants were female (62.5%) and non-Hispanic white (67.5%). The average age was 39.2 years old (standard deviation 10.9) and few participants had ever smoked cigarettes (12.5%) but most had drunk alcohol (97.5%). All participants completed all six study visits. Prior to each study visit, a small proportion of participants had used antibiotics in the past 30 days (ranging from 5.0% to 10.0%),

Table 1. Baseline descriptive characteristics of study participants (N = 40)

	N/Mean	%/SD
Age	39.2	10.9
Sex		
Male	15	37.50%
Female	25	62.50%
Education		
Bachelor's degree	3	7.50%
Master's or doctoral degree	37	92.50%
Race/ethnicity		
Non-Hispanic white	27	67.50%
Other	13	32.50%
Body mass index (kg/m ²)	25.2	5.1
Ever smoked cigarettes		
Yes	5	12.50%
No	35	87.50%
Ever drank alcohol		
Yes	39	97.50%
No	1	2.50%

Table 2. Recent exposures prior to study visits ($N = 40$)

	Used antibiotics past 30 days		Dental visit in past 2 months		Lack of adherence to preparation procedures	
	Yes	%	Yes	%	Yes	%
Visit 1	3	7.50%	8	20.00%	5	12.50%
Visit 2	2	5.00%	9	22.50%	6	15.00%
Visit 3	2	5.00%	11	27.50%	9	22.50%
Visit 4	2	5.00%	15	37.50%	10	25.00%
Visit 5	4	10.00%	20	50.00%	11	27.50%
Visit 6	3	7.50%	12	30.00%	10	25.00%

had a dental visit in the past 2 months (ranging from 20.0% to 50.0%), or did not adhere to the preparation procedures (ranging from 12.5% to 27.5%; Table 2).

Overall, the OMNIgene ORAL samples from all six visits tended to cluster together using the first two principal coordinates from each beta diversity matrix although there was overlap between some participants. The two quality control samples, the oral artificial community and the chemostat community, tended to cluster separately from the study samples and separately from each other (Supplementary Figs. S1–S3).

For the alpha diversity measures, the ICCs were generally high, particularly for Chao1 and observed species with OMNIgene ICCs of 0.73 (95% CI: 0.65–0.81) and 0.74 (95% CI: 0.66–0.82), respectively, with slightly higher ICCs for Scope mouthwash. Compared with the alpha diversity metrics, the ICCs were generally lower for phylum-level relative abundances and Scope mouthwash had a low ICC for *Fusobacteria* (ICC 0.29; 95% CI: 0.00–0.83). For the beta diversity matrices, the highest ICC was observed for Bray–Curtis of the OMNIgene ORAL samples (ICC 0.70; 95% CI: 0.66–0.74; Fig. 1; Supplementary Table S1). When we included adjustment for use of antibiotics, having a dentist visit in the past 2 months, or not adhering to the requested preparation procedures, the ICCs were not materially affected (Supplementary Fig. S4). At the genus level, the ICCs for the OMNIgene ORAL kit were generally higher than for the Scope mouthwash, but the ICCs were still high for a number of genera in the Scope mouthwash sample such as *Veillonella* (ICC 0.67; 95%

CI: 0.49–0.86) and *Megasphaera* (ICC 0.77; 95% CI: 0.64–0.89; Supplementary Fig S5; Supplementary Table S2).

For most levels from phylum to genus, the DMM clustered the OMNIgene ORAL samples into three community types (Supplementary Fig. S6). Figure 2 shows the temporal dynamics of phylum-level clusters with transition probabilities labeled on the plot. Cluster C appeared to be the most stable with a probability of 80.7% of remaining in Cluster C. The probability of remaining in Cluster A was only 59.5% and a proportion of Cluster A transitioned to Cluster B with a probability of 34.5%. However, Cluster A was the least common among participants with an average prevalence of 18.1%. Results for the transition probabilities at all taxonomic levels are presented in Supplementary Table S3.

Sample size requirements for future case–control studies considering the association between the microbiota and case status depend on the estimated ICC, the number of specimens collected per participant, the minimum detectable OR, and the P value threshold for statistical significance. From the OMNIgene ORAL ICCs, we estimated that given an ICC for the relative abundance of *Actinobacteria* was 0.46, with 1 specimen collected per participant, we would require 1,431 cases and 1,431 controls to detect an OR of 1.50 with a P value threshold of 0.05. The required sample sizes decrease for measures with higher ICCs, for larger ORs, and for increased specimens per participant. For example, with 3 specimens per participant and an OR of 3.50, a study would only require 92 cases and





Figure 1. ICCs for four alpha diversity metrics, the top four abundant phyla, and three beta diversity metrics for OMNIgene ORAL and Scope mouthwash samples.

Vogtmann et al.

**Figure 2.**

Dirichlet transition diagram. The OMNIgene ORAL samples clustered into three groups using DMM modeling of the phylum level relative abundances. The figure presents the transition probabilities between the different groups. The overall prevalence of the clusters were 18.1%, 41.3%, and 40.6% for Clusters A, B, and C, respectively.

92 controls for the relative abundance of *Actinobacteria* with a *P* value threshold of 0.05 (Table 3). Similar sample size requirements are presented for the OMNIgene ORAL samples with other *P* value thresholds (Supplementary Table S4) and from the Scope mouthwash ICCs (Supplementary Table S5).

Discussion

In this study, the oral microbiota, measured from saliva and Scope mouthwash, appear to be relatively stable over a period of 10 months. The ICCs for the alpha diversity metrics were high with ICCs greater than 0.70 for both Chao1 and observed species from the OMNIgene ORAL and Scope mouthwash. The ICCs for the relative abundance of specific phyla and beta diversity matrices were generally lower and only the ICC for Bray–Curtis from the OMNIgene ORAL reached 0.70. When we adjusted for factors which may disrupt the oral microbiota, the ICCs were similar. From the DMM, we observed that the probability of remaining in a cluster was high, such that for participants in the clusters with a high prevalence in this study there was a high probability of remaining in those clusters. The DMM analysis provided further evidence for general temporal stability of the oral microbiota. Using the estimated ICCs, for large effect sizes, multiple samples per individual offer modest advantages over a single sample, but

Table 3. Number of cases (assuming an equal number of controls) required to detect an OR with 80% power and a disease prevalence of 1% assuming 1, 2, or 3 oral samples per subject based on the ICC estimated from the OMNIgene ORAL samples with a *P* value threshold of 0.05

		Estimated ICC	#Specimens per subject	OR				
				1.50	2.00	2.50	3.00	3.50
Relative abundance of phylum-level taxa	Actinobacteria	0.46	1	1431	477	261	181	144
			2	1045	348	190	132	105
			3	916	305	167	116	92
	Bacteroidetes	0.62	1	1062	354	193	134	107
			2	860	286	157	109	87
			3	793	264	144	100	80
	Firmicutes	0.44	1	1496	498	273	190	151
			2	1077	359	196	136	109
			3	938	312	171	119	94
	Fusobacteria	0.67	1	983	327	179	124	99
			2	820	273	149	104	83
			3	766	255	140	97	77
	Proteobacteria	0.67	1	983	327	179	124	99
			2	820	273	149	104	83
			3	766	255	140	97	77
Candidate division SR1	0.73	1	902	300	164	114	91	
		2	780	260	142	99	79	
		3	739	246	135	93	74	
Alpha diversity	Chao1	0.73	1	902	300	164	114	91
			2	780	260	142	99	79
			3	739	246	135	93	74
	PD whole tree	0.45	1	1463	487	267	185	148
			2	1061	353	193	134	107
			3	926	308	169	117	93
	Observed species	0.74	1	890	296	162	113	90
			2	774	258	141	98	78
			3	735	245	134	93	74
Shannon index	0.56	1	1176	392	214	149	119	
		2	917	305	167	116	92	
		3	831	277	151	105	84	
Beta diversity	Bray Curtis distance	0.70	1	940	313	171	119	95
			2	799	266	146	101	80
			3	752	250	137	95	76
	Unweighted UniFrac distance	0.64	1	1029	343	187	130	104
			2	843	281	154	107	85
			3	782	260	142	99	79
	Weighted UniFrac distance	0.67	1	983	327	179	124	99
			2	820	273	149	104	83
			3	766	255	140	97	77

for smaller effect sizes, multiple samples per individual offers larger gains in power.

A number of previous studies have evaluated the temporal variation in oral microbiota using saliva (8–10, 14, 15, 18, 20, 23, 37), tongue swabs (11, 13, 18, 20, 21), oral wash (11, 12, 16), and plaque samples (15, 18–20, 38). Similar to our findings, the majority of previous studies generally concluded that the oral microbiota is relatively stable over time, but these measures of stability varied between studies (8–20). It has been demonstrated previously that antibiotic use disrupts gut microbiota (39–41), but antibiotics appear to only have a modest effect on the oral microbiota (13, 42, 43). In our study, adjusting for the use of antibiotics did not appear to impact the estimates of temporal stability. In addition, adjustment for not adhering to the requested preparation procedures or visiting the dentist in the past month did not substantially improve the estimates of temporal variability.

This study has some limitations. The participants in our study are unlikely to be representative of the general population given the high education status which likely leads to healthier lifestyles. In addition, we did not collect dietary information so we were unable to determine how changes in diet may affect temporal variability. However, our findings are generally in concordance with previous literature that suggests that the oral microbiota may be relatively stable over time. In addition, we only collected samples over the course of approximately 10 months, so our study cannot evaluate longer term stability. Similarly, the sample size calculations were based on ICCs derived from sampling over 10 months and these required sample sizes may differ for samples collected over longer durations.

This study also has numerous strengths. We collected data on potential exposures which may disrupt the oral microbiota to evaluate whether these affected the temporal variability. We also used two different collection methods that may be used in large-scale epidemiologic studies to determine whether temporal variability differs by method of oral sample collection. Finally, we utilized multiple microbial measures and statistical methods used in different studies to evaluate oral microbial stability.

In conclusion, in this study of 40 individuals with oral samples collected every two months over the course of about

10 months, the oral microbiota appears to be relatively stable over time, but some measures, particularly the relative abundance of specific phyla and genera, were less stable. In planning future studies, investigators will need to take into account the temporal stability of specific measures if only collecting one sample from participants and for smaller effect sizes, collecting multiple samples per individual may provide some future gains in statistical power.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: E. Vogtmann, C.C. Abnet

Development of methodology: E. Vogtmann, C.L. Dagnall, K. Jones, R. Sinha, J. Shi

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E. Vogtmann, C.L. Dagnall, A. Hutchinson, K. Jones, B.D. Hicks

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E. Vogtmann, X. Hua, L. Zhou, Y. Wan, S. Suman, B. Zhu, B.D. Hicks, R. Sinha, J. Shi, C.C. Abnet

Writing, review, and/or revision of the manuscript: E. Vogtmann, L. Zhou, C.L. Dagnall, B.D. Hicks, R. Sinha, C.C. Abnet

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.L. Dagnall, A. Hutchinson

Study supervision: E. Vogtmann, A. Hutchinson, C.C. Abnet

Acknowledgments

This study was supported by the Intramural Research Program of the National Cancer Institute (to E. Vogtmann, X. Hua, L. Zhou, Y. Wan, S. Suman, B. Zhu, C. Dagnall, A. Hutchinson, K. Jones, B. Hicks, R. Sinha, J. Shi, C. Abnet).

We would like to thank all of our participants.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 27, 2017; revised December 22, 2017; accepted February 9, 2018; published first February 23, 2018.

References

- Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Taylor PR, Mark SD. Tooth loss is associated with increased risk of total death and death from upper gastrointestinal cancer, heart disease, and stroke in a Chinese population-based cohort. *Int J Epidemiol* 2005;34:467–74.
- Polzer J, Schwahn C, Volzke H, Mundt T, Biffar R. The association of tooth loss with all-cause and circulatory mortality. Is there a benefit of replaced teeth? A systematic review and meta-analysis. *Clin Oral Investig* 2012;16:333–51.
- Abnet CC, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM. Prospective study of tooth loss and incident esophageal and gastric cancers in China. *Cancer Causes Control* 2001;12:847–54.
- Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. *Lancet Oncol* 2008;9:550–8.
- Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. *Gut* 2018;67:120–7.
- Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. *Gut* 2012;61:582–8.
- Torres PJ, Fletcher EM, Gibbons SM, Bouvet M, Doran KS, Kelley ST. Characterization of the salivary microbiome in patients with pancreatic cancer. *PeerJ* 2015;3:e1373.
- Abeles SR, Robles-Sikisaka R, Ly M, Lum AG, Salzman J, Boehm TK, et al. Human oral viruses are personal, persistent and gender-consistent. *ISME J* 2014;8:1753–67.
- Belstrom D, Holmstrup P, Bardow A, Kokaras A, Fiehn NE, Paster BJ. Temporal stability of the salivary microbiota in oral health. *PLoS ONE* 2016;11:e0147472.
- Cameron SJ, Huws SA, Hegarty MJ, Smith DP, Mur LA. The human salivary microbiome exhibits temporal stability in bacterial diversity. *FEMS Microbiol Ecol* 2015;91:fiv091.
- Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JJ, Knight R. Bacterial community variation in human body habitats across space and time. *Science* 2009;326:1694–7.
- David LA, Materna AC, Friedman J, Campos-Baptista MI, Blackburn MC, Perrotta A, et al. Host lifestyle affects human microbiota on daily time-scales. *Genome Biol* 2014;15:R89.
- Flores GE, Caporaso JC, Henley JB, Rideout JR, Domogala D, Chase J, et al. Temporal variability is a personalized feature of the human microbiome. *Genome Biol* 2014;15:531.

Vogtmann et al.

14. Lazarevic V, Whiteson K, Hernandez D, Francois P, Schrenzel J. Study of inter- and intra-individual variations in the salivary microbiota. *BMC Genomics* 2010;11:523.
15. Luo T, Srinivasan U, Ramadugu K, Shedden KA, Neiswanger K, Trumble E, et al. Effects of specimen collection methodologies and storage conditions on the short-term stability of oral microbiome taxonomy. *Appl Environ Microbiol* 2016;82:5519–29.
16. Stahringer SS, Clemente JC, Corley RP, Hewitt J, Knights D, Walters WA, et al. Nurture trumps nature in a longitudinal survey of salivary bacterial communities in twins from early adolescence to early adulthood. *Genome Research* 2012;22:2146–52.
17. Utter DR, Mark Welch JL, Borisy GG. Individuality, stability, and variability of the plaque microbiome. *Front Microbiol* 2016;7:564.
18. Zhou Y, Gao H, Mihindukulasuriya KA, La Rosa PS, Wylie KM, Vishnivetskaya T, et al. Biogeography of the ecosystems of the healthy human body. *Genome Biol* 2013;14:R1.
19. Sato Y, Yamagishi J, Yamashita R, Shinozaki N, Ye B, Yamada T, et al. Inter-individual differences in the oral bacteriome are greater than intra-day fluctuations in individuals. *PLoS ONE* 2015;10:e0131607.
20. Hall MW, Singh N, Ng KF, Lam DK, Goldberg MB, Tenenbaum HC, et al. Inter-personal diversity and temporal dynamics of dental, tongue, and salivary microbiota in the healthy oral cavity. *NPJ Biofilms and Microbiomes* 2017;3:2.
21. Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, et al. Moving pictures of the human microbiome. *Genome Biology* 2011;12:R50.
22. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. *Nature* 2014;509:357–60.
23. Takayasu L, Suda W, Takanashi K, Iioka E, Kurokawa R, Shindo C, et al. Circadian oscillations of microbial and functional composition in the human salivary microbiome. *DNA Res* 2017;24:261–70.
24. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA* 2012;307:693–703.
25. Sinha R, Abnet CC, White O, Knight R, Huttenhower C. The microbiome quality control project: baseline study design and future directions. *Genome Biol* 2015;16:276.
26. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc Natl Acad Sci USA* 2011;108:4516–22.
27. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. *ISME J* 2012;6:1621–4.
28. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat Methods* 2016;13:581–3.
29. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, et al. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Res* 2007;35:7188–96.
30. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 2010;7:335–6.
31. Chao A. Nonparametric estimation of the number of classes in a population. *Scandinavian Journal of Statistics* 1984;11:265–70.
32. Shannon CE. A mathematical theory of communication. *The Bell System Technical Journal* 1948;27:379–423.
33. Faith DP, Baker AM. Phylogenetic diversity (PD) and biodiversity conservation: some bioinformatics challenges. *Evolutionary Bioinformatics Online* 2007;2:121–8.
34. Bray JR, Curtis JT. An Ordination of the Upland Forest Communities of Southern Wisconsin. *Ecological Monographs* 1957;27:325–49.
35. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. *Appl Environ Microbiol* 2005;71:8228–35.
36. Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: generative models for microbial metagenomics. *PLoS ONE* 2012;7:e30126.
37. Pride DT, Salzman J, Haynes M, Rohwer F, Davis-Long C, White RA III, et al. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. *ISME J* 2012;6:915–26.
38. Jiang WX, Hu YJ, Gao L, He ZY, Zhu CL, Ma R, et al. The impact of various time intervals on the supragingival plaque dynamic core microbiome. *PLoS ONE* 2015;10:e0124631.
39. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci USA* 2011;108:4554–61.
40. Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. *Front Microbiol* 2015;6:1543.
41. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. *J Clin Invest* 2014;124:4212–8.
42. Zaura E, Brandt BW, Teixeira de Mattos MJ, Buijs MJ, Caspers MP, Rashid MU, et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. *mBio* 2015;6:e01693–15.
43. Abeles SR, Ly M, Santiago-Rodriguez TM, Pride DT. Effects of long term antibiotic therapy on human oral and fecal viromes. *PLoS ONE* 2015;10:e0134941.

Cancer Epidemiology, Biomarkers & Prevention

Temporal Variability of Oral Microbiota over 10 Months and the Implications for Future Epidemiologic Studies

Emily Vogtmann, Xing Hua, Liang Zhou, et al.

Cancer Epidemiol Biomarkers Prev 2018;27:594-600. Published OnlineFirst February 23, 2018.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-17-1004](https://doi.org/10.1158/1055-9965.EPI-17-1004)

Supplementary Material Access the most recent supplemental material at:
<http://cebp.aacrjournals.org/content/suppl/2018/12/13/1055-9965.EPI-17-1004.DC1>

Cited articles This article cites 43 articles, 8 of which you can access for free at:
<http://cebp.aacrjournals.org/content/27/5/594.full#ref-list-1>

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/27/5/594.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/27/5/594>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.